News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mintz Levin Represents San Diego-Based MabVax Therapeutics, Inc. In IPO Through Merger With Telik, Inc. (TELK)


7/11/2014 9:27:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Attorneys from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.'s San Diego office represented San Diego-based MabVax Therapeutics, Inc. in its previously announced merger with a wholly owned subsidiary of Telik, Inc. (NASDAQ:TELK) Prior to the July 8th merger, MabVax Therapeutics, Inc. was a privately-held cancer immunotherapy company focusing on the development of vaccine and antibody-based therapies for the treatment of cancer. Telik, Inc. is a publicly-traded clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Through the transaction, the former MabVax stockholders became the controlling stockholders of the publicly-traded Telik and MabVax’s management team became the management team of Telik, resulting in MabVax achieving access to the public markets through the merger.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES